Real-world evidence for atezolizumab with bevacizumab for unresectable hepatocellular carcinoma: a multicentre UK Midlands cohort
4 affiliations
- 1Department of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham
- 2Department of Oncology and Radiotherapy, Nottingham University Hospitals NHS Trust
- 3Department of Medical Oncology, University Hospitals Leicester
- 4Department of Medical Oncology, University Hospitals Birmingham NHS Trust
Abstract
Background The IMbrave150 trial established atezolizumab plus bevacizumab (ATE/BEV) as first-line standard of care for unresectable hepatocellular carcinoma (HCC), demonstrating superior overall survival (OS) and progression-free survival (PFS) versus sorafenib. Real-world data are required to further evaluate effectiveness and safety. Methods We conducted a retrospective multicentre analysis across three oncology centres in the Midlands, UK, with audit committee approval. Eligible patients had HCC confirmed histologically where feasible. Results As of August 2025, 233 patients were included, with a median follow-up of 17.4 months (95% CI: 12.6–23.2). Median OS was 16.5 months (95% CI: 14.2–20.7), with 6-month OS of 76.8%. Median PFS was 12.3 months (95% CI: 10.0–16.3), with 6-month PFS of 70.8%. The objective response rate was 42.9%. Treatment discontinuation occurred in 81.5% of patients, most commonly due to disease progression (47.4%), toxicity (22.6%), or liver decompensation (17.9%). Second-line therapy was administered to 39.1%. Any-grade adverse events occurred in 41.2%, with ≥grade 3 toxicity in 23.2%. Conclusions In this UK real-world cohort, ATE/BEV demonstrated survival outcomes comparable to IMBrave150, with manageable toxicity and meaningful access to subsequent therapy, supporting its effectiveness beyond clinical trial settings. Graphical Abstract
Related
- Early antibiotic exposure, but not late exposure, negatively affects the clinical outcomes of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma
- Curative Locoregional Therapy following Objective Response to Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
- Baseline Predictors, Prognostic Impact, and Risk Stratification of Early Progressive Disease on Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Multicenter Real-World Study.
- Acute colonic variceal bleeding treated with coil-assisted retrograde transvenous obliteration following atezolizumab-bevacizumab therapy for advanced hepatocellular carcinoma: A case report.
- Prognostic Significance of Response Dynamics in Atezolizumab plus Bevacizumab-Treated Hepatocellular Carcinoma: A Multicenter Real-World Validation Study.
BibTeX
@article{phillips2026realworld,
title = {{Real-world evidence for atezolizumab with bevacizumab for unresectable hepatocellular carcinoma: a multicentre UK Midlands cohort}},
author = {Richard Phillips and Harry Daniels and Marie Quinlan and Ali Suwaidan and Kaushal Maru and Jake Hancock and Mabel Teng and Jasvinder Kaur and Yuk Ting Ma and Sean Dulloo and Sadaqat Hussain and Basma Greef and Shivan Sivakumar},
journal = {BMC Cancer},
year = {2026},
month = jul,
doi = {10.1186/s12885-026-16387-3},
url = {https://doi.org/10.1186/s12885-026-16387-3},
note = {CC BY},
}
RIS
TY - JOUR
TI - Real-world evidence for atezolizumab with bevacizumab for unresectable hepatocellular carcinoma: a multicentre UK Midlands cohort
AU - Richard Phillips
AU - Harry Daniels
AU - Marie Quinlan
AU - Ali Suwaidan
AU - Kaushal Maru
AU - Jake Hancock
AU - Mabel Teng
AU - Jasvinder Kaur
AU - Yuk Ting Ma
AU - Sean Dulloo
AU - Sadaqat Hussain
AU - Basma Greef
AU - Shivan Sivakumar
PY - 2026
DA - 2026/07/01
JO - BMC Cancer
DO - 10.1186/s12885-026-16387-3
UR - https://doi.org/10.1186/s12885-026-16387-3
AB - Background The IMbrave150 trial established atezolizumab plus bevacizumab (ATE/BEV) as first-line standard of care for unresectable hepatocellular carcinoma (HCC), demonstrating superior overall survival (OS) and progression-free survival (PFS) versus sorafenib. Real-world data are required to further evaluate effectiveness and safety. Methods We conducted a retrospective multicentre analysis across three oncology centres in the Midlands, UK, with audit committee approval. Eligible patients had HCC confirmed histologically where feasible. Results As of August 2025, 233 patients were included, with a median follow-up of 17.4 months (95% CI: 12.6–23.2). Median OS was 16.5 months (95% CI: 14.2–20.7), with 6-month OS of 76.8%. Median PFS was 12.3 months (95% CI: 10.0–16.3), with 6-month PFS of 70.8%. The objective response rate was 42.9%. Treatment discontinuation occurred in 81.5% of patients, most commonly due to disease progression (47.4%), toxicity (22.6%), or liver decompensation (17.9%). Second-line therapy was administered to 39.1%. Any-grade adverse events occurred in 41.2%, with ≥grade 3 toxicity in 23.2%. Conclusions In this UK real-world cohort, ATE/BEV demonstrated survival outcomes comparable to IMBrave150, with manageable toxicity and meaningful access to subsequent therapy, supporting its effectiveness beyond clinical trial settings. Graphical Abstract
SN - 1471-2407
ER -